Brief: Biomea Fusion Top Line Data Of The 200 Mg Dose Cohorts From The Ongoing Phase Ii Clinical Study (Covalent-111)
09/12/2023 23:54
Dec 9 (Reuters) - Biomea Fusion Inc BMEA.O :
* TOP LINE DATA OF THE 200 MG DOSE COHORTS FROM THE ONGOING
PHASE
II CLINICAL STUDY (COVALENT-111)
Source text for Eikon: ID:nGNX8kwGvX
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes